- ROUNDTABLE: Pharmacy’s future in sync with technology
- Indiana Senate passes generic biologic pathway legislation
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study from NCPA sheds new light on med synchronization programs
- Reports: ESI may start 'price war' over new hepatitis C drugs
NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson plans to file for regulatory approval for 11 new drugs between 2011 and 2015, the company said Thursday in relation to a meeting between J&J’s executive committee and investors.
During the same period, J&J plans to file for approval for more than 30 extensions of existing product lines as one of several growth strategies in its pharmaceuticals segment, which generated $22.4 billion in sales last year — accounting for 36% of the company’s total sales — and made it the world’s eighth largest pharmaceutical company and fifth largest biotech company.
“Our people focus every day on addressing the world’s major unmet medical needs with superior science,” executive committee vice chairwoman Sheri McCoy said. “Since our last Pharmaceuticals Business Review with analysts in 2009, we have built a highly productive pharmaceuticals pipeline, with six key new products launching and another two pending regulatory review, some in multiple geographies.”